1. Dirks JH, de Zeeuw D, Agarwal SK, et al: Prevention of chronic kidney and vascular disease: Toward global health equity—The Bellagio 2004 Declaration. Kidney Int Suppl 98:S1-S6, 2005
2. Lysaght MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13:S37-S40, 2002 (suppl 1)
3. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:S1-266, 2002 (suppl 1)
4. US Renal Data System: USRDS 2004 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004
5. National Kidney Foundation: K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43:S1-S290, 2004 (suppl 1)
6. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Management of Dyslipidemias in Patients With Kidney Disease. Am J Kidney Dis 41:S1-S91, 2003 (suppl 3)
7. National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-S201, 2003 (suppl 3)
8. National Kidney Foundation: K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47:S1-S145, 2006 (suppl 3)
9. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis 35:S1-S140, 2000 (suppl 2)
10. National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45:S1-S153, 2005 (suppl 3)
11. Knowler WC, Bennett PH, Bottazzo GF, Doniach D: Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia 17:161-164, 1979
12. West KM: Diabetes in American Indians, in Levine R, Luft R (eds): Advances in Metabolic Disorders, vol 9. New York, NY, Academic, 1978, pp 29-47
13. Zimmet P: Globalization, coca-colonization and the chronic disease epidemic: Can the doomsday scenario be averted? J Intern Med 247:301-310, 2000
14. Engelgau MM, Geiss LS, Saaddine JB, et al: The evolving diabetes burden in the United States. Ann Intern Med 140:945-950, 2004
15. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study. Arch Intern Med 159:1450-1456, 1999
16. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291-1297, 1999
17. Gale EA: The rise of childhood type 1 diabetes in the 20th century. Diabetes 51:3353-3361, 2002
18. Boyle JP, Honeycutt AA, Narayan KM, et al: Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 24:1936-1940, 2001
19. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
20. Colagiuri S, Borch-Johnsen K, Glumer C, Vistisen D: There really is an epidemic of type 2 diabetes. Diabetologia 48:1459-1463, 2005
21. US Renal Data System: USRDS 2005 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005
22. Motala AA, Pirie FJ, Gouws E, Amod A, Omar MA: Microvascular complications in South African patients with long-duration diabetes mellitus. S Afr Med J 91:987-992, 2001
23. Wanjohi FW, Otieno FC, Ogola EN, Amayo EO: Nephropathy in patients with recently diagnosed type 2 diabetes mellitus in black Africans. East Afr Med J 79:399-404, 2002
24. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M: Rising prevalence of NIDDM in an urban population in India. Diabetologia 40:232-237, 1997
25. Simmons D, Schaumkel J, Cecil A, Scott DJ, Kenealy T: High impact of nephropathy on five-year mortality rates among patients with type 2 diabetes mellitus from a multi-ethnic population in New Zealand. Diabet Med 16:926-931, 1999
26. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU: Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 21:530-534, 1998
27. Wu AY, Kong NC, de Leon FA, et al: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: The MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17-26, 2005
28. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF: Diabetes in Africans. Part 1: Epidemiology and clinical specificities. Diabetes Metab 27:628-634, 2001
29. Earle KK, Porter KA, Ostberg J, Yudkin JS: Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant 16:286-290, 2001
30. Koppiker N, Feehally J, Raymond N, Abrams KR, Burden AC: Rate of decline in renal function in Indo-Asians and whites with diabetic nephropathy. Diabet Med 15:60-65, 1998
31. Chandie Shaw PK, van Es LA, Paul LC, Rosendaal FR, Souverijn JH, Vandenbroucke JP: Renal disease in relatives of Indo-Asian type 2 diabetic patients with end-stage diabetic nephropathy. Diabetologia 46:618-624, 2003
32. Chandie Shaw PK, Vandenbroucke JP, Tjandra YI, et al: Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in The Netherlands. Diabetologia 45:337-341, 2002
33. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414:782-787, 2001
34. Standards of medical care in diabetes—2006. Diabetes Care 29:S4-S42, 2006 (suppl 1)
35. Molitch ME, DeFronzo RA, Franz MJ, et al: Nephropathy in diabetes. Diabetes Care 27:S79-S83, 2004 (suppl 1)
36. Feldt-Rasmussen B: Microalbuminuria and clinical nephropathy in type 1 (insulin-dependent) diabetes mellitus: Pathophysiological mechanisms and intervention studies. Dan Med Bull 36:405-415, 1989
37. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
38. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO: Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive summary: Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105:2231-2239, 2002
39. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
40. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413-1418, 1997
41. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232, 2003
42. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27:2033-2039, 1996
43. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093-1100, 2000
44. Foley RN, Murray AM, Li S, et al: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16:489-495, 2005
45. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
46. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353:617-622, 1999
47. Carey VJ, Walters EE, Colditz GA, et al: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 145:614-619, 1997
48. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17:961-969, 1994
49. Kaye SA, Folsom AR, Sprafka JM, Prineas RJ, Wallace RB: Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 44:329-334, 1991
50. Lundgren H, Bengtsson C, Blohme G, Lapidus L, Sjostrom L: Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: Results from a prospective population study in Gothenburg, Sweden. Int J Obes 13:413-423, 1989
51. Ohlson LO, Larsson B, Svardsudd K, et al: The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 Years of follow-up of the participants in the study of men born in 1913. Diabetes 34:1055-1058, 1985
52. Sargeant LA, Bennett FI, Forrester TE, Cooper RS, Wilks RJ: Predicting incident diabetes in Jamaica: The role of anthropometry. Obes Res 10:792-798, 2002
53. Warne DK, Charles MA, Hanson RL, et al: Comparison of body size measurements as predictors of NIDDM in Pima Indians. Diabetes Care 18:435-439, 1995
54. Wei M, Gaskill SP, Haffner SM, Stern MP: Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans—A 7-year prospective study. Obes Res 5:16-23, 1997
55. Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC: Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care 26:2556-2561, 2003
56. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278:F817-F822, 2000
57. Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 26:610-615, 1995
58. Folsom AR, Kushi LH, Hong CP: Physical activity and incident diabetes mellitus in postmenopausal women. Am J Public Health 90:134-138, 2000
59. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr: Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325:147-152, 1991
60. Kriska AM, Saremi A, Hanson RL, et al: Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population. Am J Epidemiol 158:669-675, 2003
61. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH: A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 268:63-67, 1992
62. Manson JE, Rimm EB, Stampfer MJ, et al: Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 338:774-778, 1991
63. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
64. Pan XR, Li GW, Hu YH, et al: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
65. Tuomilehto J, Lindstrom J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
66. Molitch ME, Fujimoto W, Hamman RF, Knowler WC: The diabetes prevention program and its global implications. J Am Soc Nephrol 14:S103-S107, 2003 (suppl 2)
67. Ramachandran A, Snehalatha C, Vinitha R, et al: Prevalence of overweight in urban Indian adolescent school children. Diabetes Res Clin Pract 57:185-190, 2002
68. Pazmino PA, Pazmino AK: Diabetic renal failure in Texas: Influence of ethnicity and household income. Tex Med 99:57-65, 2003
69. Brancati FL, Whelton PK, Kuller LH, Klag MJ: Diabetes mellitus, race, and socioeconomic status. A population-based study. Ann Epidemiol 6:67-73, 1996
70. Hazuda HP, Haffner SM, Stern MP, Eifler CW: Effects of acculturation and socioeconomic status on obesity and diabetes in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol 128:1289-1301, 1988
71. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M: Type 2 diabetes in the young: The evolving epidemic: The International Diabetes Federation Consensus Workshop. Diabetes Care 27:1798-1811, 2004
72. Singh R, Shaw J, Zimmet P: Epidemiology of childhood type 2 diabetes in the developing world. Pediatr Diabetes 5:154-168, 2004
73. Acton KJ, Burrows NR, Moore K, Querec L, Geiss LS, Engelgau MM: Trends in diabetes prevalence among American Indian and Alaska native children, adolescents, and young adults. Am J Public Health 92:1485-1490, 2002
74. Kitagawa T, Owada M, Urakami T, Yamauchi K: Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 37:111-115, 1998
75. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T: Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 28:1876-1881, 2005
76. Dabelea D, Hanson RL, Bennett PH, Roumain J, Knowler WC, Pettitt DJ: Increasing prevalence of type II diabetes in American Indian children. Diabetologia 41:904-910, 1998
77. Pettitt DJ, Baird HR, Aleck KA, Bennett PH, Knowler WC: Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N Engl J Med 308:242-245, 1983
78. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al: Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr 136:664-672, 2000
79. Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC: Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 26:76-81, 2003
80. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG: Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296:421-426, 2006
81. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M: Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: General description and morbidity. Diabetologia 44:S3-S13, 2001 (suppl 2)
82. Lee ET, Lu M, Bennett PH, Keen H: Vascular disease in younger-onset diabetes: Comparison of European, Asian and American Indian cohorts of the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44:S78-S81, 2001 (suppl 2)
83. Uchigata Y: Long-term outcome of type 2 diabetes in adolescence, in Silink M, Kida K, Rosenbloom AL (eds): Type 2 Diabetes in Childhood and Adolescence: A Global Perspective. New York, NY, Dunitz, 2003, pp 187-210
84. Yokoyama H, Okudaira M, Otani T, et al: Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care 20:844-847, 1997
85. Brown AF, Mangione CM, Saliba D, Sarkisian CA: Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51:S265-S280, 2003 (suppl)
86. Pettitt DJ, Knowler WC: Diabetes and obesity in the Pima Indians: A crossgenerational vicious cycle. J Obes Weight Regul 7:61-65, 1988 (Note: Reference link was unavailable at time of online publication)
87. Nelson RG, Morgenstern H, Bennett PH: Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 47:1489-1493, 1998
88. Gregg EW, Beckles GL, Williamson DF, et al: Diabetes and physical disability among older U.S. adults. Diabetes Care 23:1272-1277, 2000
89. Volpato S, Blaum C, Resnick H, Ferrucci L, Fried LP, Guralnik JM: Comorbidities and impairments explaining the association between diabetes and lower extremity disability: The Women's Health and Aging Study. Diabetes Care 25:678-683, 2002
90. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984
91. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532, 1984
92. McKenna MT, Michaud CM, Murray CJ, Marks JS: Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med 28:415-423, 2005
93. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB: Mortality among diabetics in a national sample. Am J Epidemiol 128:389-401, 1988
94. Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596, 1985
95. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC: Effect of proteinuria on mortality in NIDDM. Diabetes 37:1499-1504, 1988
96. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: The WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 12:149-155, 1995
97. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22, 2002
98. Colhoun HM, Betteridge DJ, Durrington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
99. Tonelli M, Keech A, Shepherd J, et al: Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16:3748-3754, 2005
100. Wanner C, Krane V, Marz W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005
101. Wackers FJ, Young LH, Inzucchi SE, et al: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study. Diabetes Care 27:1954-1961, 2004
102. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:282-292, 2004
103. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003
104. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
105. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
106. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001
107. Tokmakova MP, Skali H, Kenchaiah S, et al: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) Study. Circulation 110:3667-3673, 2004
108. Bakris GL, Fonseca V, Katholi RE, et al: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292:2227-2236, 2004
109. Malmberg K, Ryden L, Efendic S, et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995
110. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001
111. Yusuf S, Mehta SR, Diaz R, et al: Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J 148:1068-1078, 2004
112. Mehta SR, Yusuf S, Diaz R, et al: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 293:437-446, 2005
113. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 354:449-461, 2006
114. Malmberg K, Ryden L, Wedel H, et al: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 26:650-661, 2005
115. Nathan DM, Cleary PA, Backlund JY, et al: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
116. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
117. Dormandy JA, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366:1279-1289, 2005
118. Kao J, Tobis J, McClelland RL, et al: Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 93:1347-1350, A1345, 2004
119. Gibler WB, Cannon CP, Blomkalns AL, et al: Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: A scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 111:2699-2710, 2005
120. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724, 2003
121. Reddan DN, Szczech L, Bhapkar MV, et al: Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant 20:2105-2112, 2005
122. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555-562, 2002
123. Wright RS, Reeder GS, Herzog CA, et al: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137:563-570, 2002
124. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA: Survival after coronary revascularization among patients with kidney disease. Circulation 110:1890-1895, 2004
125. Reddan DN, Szczech LA, Tuttle RH, et al: Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 14:2373-2380, 2003
126. Ix JH, Mercado N, Shlipak MG, et al: Association of chronic kidney disease with clinical outcomes after coronary revascularization: The Arterial Revascularization Therapies Study (ARTS). Am Heart J 149:512-519, 2005
127. Moussa I, Leon MB, Baim DS, et al: Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109:2273-2278, 2004
128. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112:2175-2183, 2005
129. Hermiller JB, Raizner A, Cannon L, et al: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 45:1172-1179, 2005
130. Mehilli J, Kastrati A, Schuhlen H, et al: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627-3635, 2004
131. Marso SP, Ellis SG, Tuzcu M, et al: The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 33:1269-1277, 1999
132. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
133. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 290:2159-2167, 2003
134. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
135. Levin SR, Coburn JW, Abraira C, et al: Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 23:1478-1485, 2000
136. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
137. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23:B21-B29, 2000 (suppl 2)
138. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
139. Brocco E, Velussi M, Cernigoi AM, et al: Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. J Nephrol 14:461-471, 2001
140. Holman RR, Dornan TL, Mayon-White V, et al: Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1:204-208, 1983
141. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H: Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. Br Med J 286:598-602, 1983
142. Gerich JE, Meyer C, Woerle HJ, Stumvoll M: Renal gluconeogenesis: Its importance in human glucose homeostasis. Diabetes Care 24:382-391, 2001
143. Hasslacher C, Wittmann W: [Severe hypoglycemia in diabetics with impaired renal function]. Dtsch Med Wochenschr 128:253-256, 2003
144. Muhlhauser I, Toth G, Sawicki PT, Berger M: Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 14:344-346, 1991
145. Yu CC, Wu MS, Wu CH, et al: Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 17:262-268, 1997
146. Morioka T, Emoto M, Tabata T, et al: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24:909-913, 2001
147. Brocco E, Fioretto P, Mauer M, et al: Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int Suppl 63:S40-S44, 1997
148. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P: Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26:S8-S14, 2000 (suppl 4)
149. de Courten MP, Pettitt DJ, Knowler WC: Hypertension in Pima Indians: Prevalence and predictors. Public Health Rep 111:S40-S43, 1996 (suppl 2)
150. Go RC, Desmond R, Roseman JM, Bell DS, Vanichanan C, Acton RT: Prevalence and risk factors of microalbuminuria in a cohort of African-American women with gestational diabetes. Diabetes Care 24:1764-1769, 2001
151. Parving HH, Hommel E, Mathiesen E, et al: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J 296:156-160, 1988
152. Tobe SW, McFarlane PA, Naimark DM: Microalbuminuria in diabetes mellitus. CMAJ 167:499-503, 2002
153. Wachtell K, Palmieri V, Olsen MH, et al: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Losartan Intervention for Endpoint Reduction. Am Heart J 143:319-326, 2002
154. Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
155. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10:185-192, 1996
156. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ 305:981-985, 1992
157. Chan JC, Ko GT, Leung DH, et al: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590-600, 2000
158. De Cesaris R, Ranieri G, Andriani A, et al: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin Pharmacol Ther 60:472-478, 1996
159. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99:497-504, 1995
160. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991
161. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
162. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286-289, 1996
163. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
164. Schnack C, Hoffmann W, Hopmeier P, Schernthaner G: Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 39:1611-1616, 1996
165. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 8:876-883, 1995
166. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271:275-279, 1994
167. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
168. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
169. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
170. Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 14:295-301, 2000
171. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 34:809-817, 1999
172. Rahman M, Pressel S, Davis BR, et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165:936-946, 2005
173. Bakris GL, Weir MR, Shanifar S, et al: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL Study. Arch Intern Med 163:1555-1565, 2003
174. Standards of medical care in diabetes. Diabetes Care 28:S4-S36, 2005 (suppl 1)
175. Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
176. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB: Lipid control in the management of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Ann Intern Med 140:644-649, 2004
177. Vijan S, Hayward RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians. Ann Intern Med 140:650-658, 2004
178. Wright JD, Wang C-Y, Kennedy-Stephenson J, Ervin RB: Dietary intake of ten key nutrients for public health, United States: 1999-2000. Hyattsville, MD, Centers for Disease Control and Prevention, National Center for Health Statistics, 2003, pp 1-4
179. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31:954-961, 1998
180. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124:627-632, 1996
181. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62:220-228, 2002
182. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A: Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. Eur J Clin Nutr 57:1292-1294, 2003
183. Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ: Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16:483-492, 1993
184. Meloni C, Morosetti M, Suraci C, et al: Severe dietary protein restriction in overt diabetic nephropathy: Benefits or risks? J Ren Nutr 12:96-101, 2002
185. Pecis M, de Azevedo MJ, Gross JL: Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care 17:665-672, 1994
186. Raal FJ, Kalk WJ, Lawson M, et al: Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: A 6-mo prospective study. Am J Clin Nutr 60:579-585, 1994
187. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
188. Gin H, Aparicio M, Potaux L, et al: Low-protein, low-phosphorus diet and tissue insulin sensitivity in insulin-dependent diabetic patients with chronic renal failure. Nephron 57:411-415, 1991
189. Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH: Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Kidney Int 55:621-628, 1999
190. Hostetter TH, Meyer TW, Rennke HG, Brenner BM: Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509-517, 1986
191. Meek RL, Cooney SK, Flynn SD, et al: Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol Renal Physiol 285:F79-F86, 2003
192. Tuttle KR, Bruton JL: Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42:167-173, 1992
193. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA: Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324:1626-1632, 1991
194. Tuttle KR, Johnson EC, Cooney SK, et al: Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int 67:953-968, 2005
195. Tuttle KR, Puhlman ME, Cooney SK, Short RA: Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol Renal Physiol 282:F103-F112, 2002
196. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 82:5963-5967, 1985
197. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC: The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med 138:460-467, 2003
198. Wrone EM, Carnethon MR, Palaniappan L, Fortmann SP: Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:580-587, 2003
199. Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001
200. Appel LJ, Sacks FM, Carey VJ, et al: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 294:2455-2464, 2005
201. He J, Gu D, Wu X, et al: Effect of soybean protein on blood pressure: A randomized, controlled trial. Ann Intern Med 143:1-9, 2005
202. Jibani MM, Bloodworth LL, Foden E, Griffiths KD, Galpin OP: Predominantly vegetarian diet in patients with incipient and early clinical diabetic nephropathy: Effects on albumin excretion rate and nutritional status. Diabet Med 8:949-953, 1991
203. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001
204. Ahmad J, Shafique S, Abidi SM, Parwez I: Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 60:131-138, 2003
205. Cordonnier DJ, Pinel N, Barro C, et al: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 10:1253-1263, 1999
206. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl 45:S161-S164, 1994
207. Sano T, Hotta N, Kawamura T, et al: Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study. Diabet Med 13:120-124, 1996
208. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 319:24-25, 1999
209. Andersen S, Brochner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296-3302, 2003
210. Atkins RC, Briganti EM, Lewis JB, et al: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45:281-287, 2005
211. de Zeeuw D, Remuzzi G, Parving HH, et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921-927, 2004
212. de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65:2309-2320, 2004
213. Calvo G, de Andres-Trelles F: Albuminuria as a surrogate marker for drug development: A European Regulatory perspective. Kidney Int Suppl 92:S126-S127, 2004
214. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727, 2002
215. Kidney Early Evaluation Program. Am J Kidney Dis 45:S1-S135, 2005 (suppl 2)
216. Hall JE, Henegar JR, Dwyer TM, et al: Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 11:41-54, 2004
217. Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J: Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 5:386-392, 2003
218. Iseki K: Factors influencing the development of end-stage renal disease. Clin Exp Nephrol 9:5-14, 2005
219. Saxena A, Chopra R: Renal risks of an emerging “epidemic” of obesity: The role of adipocyte-derived factors. Dial Transplant 33:11-21, 2004 (Note: Reference link was unavailable at time of online publication)
220. Soto FC, Higa-Sansone G, Copley JB, et al: Renal failure, glomerulonephritis and morbid obesity: Improvement after rapid weight loss following laparoscopic gastric bypass. Obes Surg 15:137-140, 2005
221. Wiggins KJ, Johnson DW: The influence of obesity on the development and survival outcomes of chronic kidney disease. Adv Chronic Kidney Dis 12:49-55, 2005
222. Mogensen CE, Chachati A, Christensen CK, et al: Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest 9:85-95, 1985
223. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T: The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diabet Med 12:482-487, 1995
224. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 49:1399-1408, 2000
225. Forsblom CM, Groop PH, Ekstrand A, Groop LC: Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 305:1051-1053, 1992
226. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293, 2003
227. Araki S, Haneda M, Sugimoto T, et al: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983-2987, 2005
228. Caramori ML, Kim Y, Huang C, et al: Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51:506-513, 2002
229. Fioretto P, Steffes MW, Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43:1358-1364, 1994
230. Fioretto P, Mauer M, Carraro A, et al: Renal structural changes in non-insulin-dependent diabetes mellitus. Am J Hypertens 10:184S-188S, 1997 (suppl 1)
231. Krolewski M, Eggers PW, Warram JH: Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study. Kidney Int 50:2041-2046, 1996
232. Microalbuminuria Collaborative Study Group: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study. United Kingdom. BMJ 306:1235-1239, 1993
233. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int 41:836-839, 1992
234. MacLeod JM, Lutale J, Marshall SM: Albumin excretion and vascular deaths in NIDDM. Diabetologia 38:610-616, 1995
235. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2:530-533, 1988
236. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study. Diabetologia 37:278-285, 1994
237. Lloyd CE, Stephenson J, Fuller JH, Orchard TJ: A comparison of renal disease across two continents; The epidemiology of diabetes complications study and the EURODIAB IDDM Complications Study. Diabetes Care 19:219-225, 1996
238. Marshall SM, Alberti KG: Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and non-insulin-dependent diabetes. Q J Med 70:61-71, 1989
239. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane AW: Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 38:1602-1610, 1989
240. Nelson RG, Kunzelman CL, Pettitt DJ, Saad MF, Bennett PH, Knowler WC: Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 32:870-876, 1989
241. Simmons D, Shaw LM, Scott DJ, Kenealy T, Scragg RK: Diabetic nephropathy and microalbuminuria in the community. The South Auckland Diabetes Survey. Diabetes Care 17:1404-1410, 1994
242. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930-937, 1996
243. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM: Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16:459-466, 2005
244. Ibrahim H, Mondress M, Tello A, Fan Y, Koopmeiners J, Thomas W: An alternative formula to the Cockcroft-Gault and the Modification of Diet in Renal Diseases formulas in predicting GFR in individuals with type 1 diabetes. J Am Soc Nephrol 16:1051-1060, 2005
245. Caramori ML, Fioretto P, Mauer M: Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes 52:1036-1040, 2003
246. Lane PH, Steffes MW, Mauer SM: Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 41:581-586, 1992
247. Brito PL, Fioretto P, Drummond K, et al: Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int 53:754-761, 1998
248. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
249. Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving HH: Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24:1972-1977, 2001
250. Viberti GC, Bilous RW, Mackintosh D, Keen H: Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med 74:256-264, 1983
251. Parving HH, Gall MA, Skott P, et al: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41:758-762, 1992
252. Nosadini R, Velussi M, Brocco E, et al: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49:476-484, 2000
253. Amoah E, Glickman JL, Malchoff CD, Sturgill BC, Kaiser DL, Bolton WK: Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II disease presenting with renal dysfunction. Am J Nephrol 8:204-211, 1988
254. Christensen PK, Gall MA, Parving HH: Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. Diabetes Care 23:B14-B20, 2000 (suppl 2)
255. Fioretto P, Mauer M, Brocco E, et al: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569-1576, 1996
256. John GT, Date A, Korula A, Jeyaseelan L, Shastry JC, Jacob CK: Nondiabetic renal disease in noninsulin-dependent diabetics in a south Indian hospital. Nephron 67:441-443, 1994
257. Kleinknecht D, Bennis D, Altman JJ: Increased prevalence of non-diabetic renal pathology in type II diabetes mellitus. Nephrol Dial Transplant 7:1258-1259, 1992
258. Mak SK, Gwi E, Chan KW, et al: Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 12:2588-2591, 1997
259. Olsen S, Mogensen CE: How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 39:1638-1645, 1996
260. Richards NT, Greaves I, Lee SJ, Howie AJ, Adu D, Michael J: Increased prevalence of renal biopsy findings other than diabetic glomerulopathy in type II diabetes mellitus. Nephrol Dial Transplant 7:397-399, 1992
261. Serra A, Romero R, Bayes B, Lopez D, Bonet J: Is there a need for changes in renal biopsy criteria in proteinuria in type 2 diabetes? Diabetes Res Clin Pract 58:149-153, 2002
262. Wong TY, Choi PC, Szeto CC, et al: Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 25:900-905, 2002
263. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N: Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: The EURODIAB Prospective Complications Study. Diabetologia 47:1020-1028, 2004
264. Hovind P, Tarnow L, Parving HH: Remission and regression of diabetic nephropathy. Curr Hypertens Rep 6:377-382, 2004
265. Bognetti E, Calori G, Meschi F, Macellaro P, Bonfanti R, Chiumello G: Prevalence and correlations of early microvascular complications in young type I diabetic patients: Role of puberty. J Pediatr Endocrinol Metab 10:587-592, 1997
266. Holl RW, Grabert M, Thon A, Heinze E: Urinary excretion of albumin in adolescents with type 1 diabetes: Persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care 22:1555-1560, 1999
267. Holl RW, Pavlovic M, Heinze E, Thon A: Circadian blood pressure during the early course of type 1 diabetes. Analysis of 1,011 ambulatory blood pressure recordings in 354 adolescents and young adults. Diabetes Care 22:1151-1157, 1999
268. Kostraba JN, Dorman JS, Orchard TJ, et al: Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 12:686-693, 1989
269. Olsen BS, Sjolie AK, Hougaard P, et al: The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications 18:160-164, 2004
270. Pavlovic M, Holl RW, Haeberle U, et al: Angiotensin I converting enzyme and angiotensinogen gene polymorphisms related to 24-h blood pressure in paediatric type I diabetes mellitus. Eur J Pediatr 158:18-23, 1999
271. Drummond K, Mauer M: The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580-1587, 2002
272. Nelson RG, Newman JM, Knowler WC, et al: Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 31:730-736, 1988
273. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195-200, 2004
274. Eiro M, Katoh T, Watanabe T: Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 9:40-45, 2005
275. Whittier WL, Korbet SM: Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol 15:142-147, 2004
276. Korbet SM: Percutaneous renal biopsy. Semin Nephrol 22:254-267, 2002
277. Whittier WL, Korbet SM: Renal biopsy: update. Curr Opin Nephrol Hypertens 13:661-665, 2004
278. Manno C, Strippoli GF, Arnesano L, et al: Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 66:1570-1577, 2004
279. Mattix H, Singh AK: Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens 8:715-718, 1999
280. Mendelssohn DC, Cole EH: Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Am J Kidney Dis 26:580-585, 1995
281. Cahill RA, McGreal GT, Crowe BH, et al: Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg 200:564-573; quiz, A559-A561, 2005
282. Donovan KL, Thomas DM, Wheeler DC, Macdougall IC, Williams JD: Experience with a new method for percutaneous renal biopsy. Nephrol Dial Transplant 6:731-733, 1991
283. Kearon C, Hirsh J: Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506-1511, 1997
284. Nass K, O'Neill WC: Bedside renal biopsy: Ultrasound guidance by the nephrologist. Am J Kidney Dis 34:955-959, 1999
285. Peterson P, Hayes TE, Arkin CF, et al: The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 133:134-139, 1998
286. Stiles KP, Hill C, LeBrun CJ, Reinmuth B, Yuan CM, Abbott KC: The impact of bleeding times on major complication rates after percutaneous real-time ultrasound-guided renal biopsies. J Nephrol 14:275-279, 2001
287. Zeigler ZR, Megaludis A, Fraley DS: Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 39:90-95, 1992
288. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348:491-499, 2003
289. Barrett BJ, Parfrey PS, Vavasour HM, et al: Contrast nephropathy in patients with impaired renal function: High versus low osmolar media. Kidney Int 41:1274-1279, 1992
290. Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The Iohexol Cooperative Study. Kidney Int 47:254-261, 1995
291. Parfrey PS, Griffiths SM, Barrett BJ, et al: Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143-149, 1989
292. Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259-2264, 2002
293. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 103:368-375, 1997
294. Nolin TD, Himmelfarb J, Matzke GR: Drug-induced kidney disease, in DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Physiological Approach. New York, NY, McGraw-Hill, 2005, pp 871-890
295. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 291:2328-2334, 2004
296. Sadeghi HM, Stone GW, Grines CL, et al: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108:2769-2775, 2003
297. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89:615-620, 1990
298. Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329-336, 2002
299. Thomsen HS: Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 181:1463-1471, 2003
300. Marenzi G, Marana I, Lauri G, et al: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349:1333-1340, 2003
301. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65:1366-1374, 2004
302. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 43:1-9, 2004
303. Barrett BJ, Parfrey PS: Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 354:379-386, 2006
304. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. Kidney Int 60:219-227, 2001
305. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS: A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50:2842-2849, 2001
306. Hovind P, Tarnow L, Rossing P, et al: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. BMJ 328:1105, 2004
307. Agardh CD, Agardh E, Torffvit O: The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: A 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 35:113-121, 1997
308. Osterby R, Hartmann A, Bangstad HJ: Structural changes in renal arterioles in type I diabetic patients. Diabetologia 45:542-549, 2002
309. Torffvit O, Agardh CD: The predictive value of albuminuria for cardiovascular and renal disease. A 5-year follow-up study of 476 patients with type I diabetes mellitus. J Diabetes Complications 7:49-56, 1993
310. Schultz CJ, Neil HA, Dalton RN, Dunger DB: Oxforn Regional Prospective Study G: Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 23:1811-1815, 2000
311. Rachmani R, Levi Z, Lidar M, Slavachevski I, HalfOnn E, Ravid M: Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: Lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 49:187-194, 2000
312. Nelson RG, Bennett PH, Beck GJ, et al: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 335:1636-1642, 1996
313. Nelson RG, Knowler WC, McCance DR, et al: Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia 36:1087-1093, 1993
314. Sosenko JM, Hu D, Welty T, Howard BV, Lee E, Robbins DC: Albuminuria in recent-onset type 2 diabetes: The Strong Heart Study. Diabetes Care 25:1078-1084, 2002
315. Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS: Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18:1013-1016, 1995
316. Torffvit O, Agardh CD: The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J Diabetes Complications 15:307-313, 2001
317. John L, Rao PS, Kanagasabapathy AS: Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care 17:888-890, 1994
318. Bruno G, Biggeri A, Merletti F, et al: Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: A 10-year prospective study. Diabetes Care 26:2353-2358, 2003
319. Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43:661-667, 1993
320. Harris RD, Steffes MW, Bilous RW, Sutherland DE, Mauer SM: Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 40:107-114, 1991
321. Ellis EN, Steffes MW, Goetz FC, Sutherland DE, Mauer SM: Glomerular filtration surface in type I diabetes mellitus. Kidney Int 29:889-894, 1986
322. Fioretto P, Steffes MW, Sutherland DE, Mauer M: Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. Kidney Int 48:1929-1935, 1995
323. Najafian B, Kim Y, Crosson JT, Mauer M: Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J Am Soc Nephrol 14:908-917, 2003
324. Bangstad HJ, Osterby R, DahlJorgensen K, et al: Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36:523-529, 1993
325. Ellis EN, Warady BA, Wood EG, et al: Renal structural-functional relationships in early diabetes mellitus. Pediatr Nephrol 11:584-591, 1997
326. Bjorn SF, Bangstad HJ, Hanssen KF, et al: Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 38:1197-1204, 1995
327. White KE, Bilous RW: Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 11:1667-1673, 2000
328. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH: Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 58:1719-1731, 2000
329. Pagtalunan ME, Miller PL, JumpingEagle S, et al: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342-348, 1997
330. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH: Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. Nephrol Dial Transplant 16:2337-2347, 2001
331. Matsumae T, Jimi S, Uesugi N, Takebayashi S, Naito S: Clinical and morphometrical interrelationships in patients with overt nephropathy induced by non-insulin-dependent diabetes mellitus. A light- and electron-microscopy study. Nephron 81:41-48, 1999
332. Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 42:1341-1344, 1999
333. Osterby R, Tapia J, Nyberg G, et al: Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 109:751-761, 2001
334. Lemley KV, Abdullah I, Myers BD, et al: Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 58:1228-1237, 2000
335. Klein R, Zinman B, Gardiner R, et al: ReninAngiotensin SS: The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: The Renin-Angiotensin System Study. Diabetes 54:527-533, 2005
336. Schwartz MM, Lewis EJ, LeonardMartin T, Lewis JB, Batlle D: Renal pathology patterns in type II diabetes mellitus: Relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 13:2547-2552, 1998
337. Kanauchi M, Kawano T, Uyama H, Shiiki H, Dohi K: Discordance between retinopathy and nephropathy in type 2 diabetes. Nephron 80:171-174, 1998
338. Stone GW, McCullough PA, Tumlin JA, et al: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 290:2284-2291, 2003
339. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 31:674-680, 1998
340. Wang A, Holcslaw T, Bashore TM, et al: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57:1675-1680, 2000
341. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416-1420, 1994
342. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am Heart J 143:894-903, 2002
343. Weisberg LS, Kurnik PB, Kurnik BR: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 45:259-265, 1994
344. Kini AA, Sharma SK: Managing the high-risk patient: Experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2:S25, 2001 (suppl 1)
345. Louis BM, Hoch BS, Hernandez C, et al: Protection from the nephrotoxicity of contrast dye. Ren Fail 18:639-646, 1996
346. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N: The role of theophylline in contrast-induced nephropathy: A case-control study. Nephrol Dial Transplant 17:1936-1941, 2002
347. Kapoor A, Sinha N, Sharma RK, et al: Use of dopamine in prevention of contrast induced acute renal failure—A randomised study. Int J Cardiol 53:233-236, 1996
348. Sterner G, Frennby B, Kurkus J, Nyman U: Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol 34:323-326, 2000
349. Madyoon H: Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med 2:S26-30, 2001 (suppl 1)
350. Taliercio CP, Vlietstra RE, Ilstrup DM, et al: A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 17:384-390, 1991
351. Lautin EM, Freeman NJ, Schoenfeld AH, et al: Radiocontrast-associated renal dysfunction: A comparison of lower-osmolality and conventional high-osmolality contrast media. AJR Am J Roentgenol 157:59-65, 1991
352. Lundqvist S, Holmberg G, Jakobsson G, et al: Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function. Acta Radiol 39:362-367, 1998
353. Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J: Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Diabetes Care 19:313-317, 1996
354. Chantelau E, Wichmann P: Pathological proteinuria in patients with insulin-dependent diabetes mellitus: Relation to intensive insulin therapy. Exp Clin Endocrinol 99:164-168, 1992
355. Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O'Brien D: Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261:1155-1160, 1989
356. Coonrod BA, Ellis D, Becker DJ, et al: Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16:1376-1383, 1993
357. Klein R, Klein BE, Moss SE: The incidence of gross proteinuria in people with insulin-dependent diabetes mellitus. Arch Intern Med 151:1344-1348, 1991
358. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332:1251-1255, 1995
359. McCance DR, Hadden DR, Atkinson AB, Johnston H, Kennedy L: The relationship between long-term glycaemic control and diabetic nephropathy. Q J Med 82:53-61, 1992
360. The Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. N Engl J Med 311:365-372, 1984
361. Beck-Nielsen H, Olesen T, Mogensen CE, et al: Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. Diabetes Res 15:185-190, 1990
362. Dahl-Jorgensen K, Bjoro T, Kierulf P, Sandvik L, Bangstad HJ, Hanssen KF: Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. Kidney Int 41:920-923, 1992
363. Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O: Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. Acta Endocrinol (Copenh) 117:19-25, 1988
364. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 2:1300-1304, 1986
365. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T: Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: An update of the Steno studies. Diabetologia 34:164-170, 1991
366. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T: Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 34:S74-S79, 1985 (suppl 3)
367. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341:1306-1309, 1993
368. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703-1720, 1995
369. Gilbert RE, Tsalamandris C, Bach LA, et al: Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 44:855-859, 1993
370. Kawazu S, Tomono S, Shimizu M, et al: The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Complications 8:13-17, 1994
371. Klein R, Klein BE, Moss SE, Cruickshanks KJ: Ten-year incidence of gross proteinuria in people with diabetes. Diabetes 44:916-923, 1995
372. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH: Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 18:182-187, 1995
373. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R: Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 21:116-120, 1998
374. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 22:743-751, 1999
375. Mulec H, Blohme G, Grande B, Bjorck S: The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 13:651-655, 1998
376. Nyberg G, Blohme G, Norden G: Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30:82-86, 1987
377. Breyer JA, Bain RP, Evans JK, et al: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 50:1651-1658, 1996
378. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience. Am J Kidney Dis 26:99-107, 1995
379. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17:7-12, 2003
380. Imano E, Kanda T, Nakatani Y, et al: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21:2135-2139, 1998
381. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H: Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50:1193-1196, 2001
382. Nakamura T, Ushiyama C, Suzuki S, et al: Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 18:308-313, 2001
383. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE system of intensive diabetes self-management—2002 Update. Endocr Pract 8:S40-S82, 2002 (suppl 1)
384. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
385. Asplund K, Wiholm BE, Lundman B: Severe hypoglycaemia during treatment with glipizide. Diabet Med 8:726-731, 1991
386. Jonsson A, Rydberg T, Sterner G, Melander A: Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53:429-435, 1998
387. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V: Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39:1617-1624, 1996
388. Inoue T, Shibahara N, Miyagawa K, et al: Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60:90-95, 2003
389. Nagai T, Imamura M, Iizuka K, Mori M: Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 59:191-194, 2003
390. Schumacher S, Abbasi I, Weise D, et al: Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147-152, 2001
391. Davidson MB, Peters AL: An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 102:99-110, 1997
392. Thompson-Culkin K, Zussman B, Miller AK, Freed MI: Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 30:391-399, 2002
393. Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG: Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 13:514-519, 1996
394. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39:297-307, 2002
395. Little RR, Tennill AL, Rohlfing C, et al: Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem 48:784-786, 2002
396. Saloranta C, Groop L, Ylinen K, Teramo K, Tolppanen EM, Tallgren LG: The usefulness of micro- and macrochromatographic determinations of glycohemoglobin in diabetic patients with nephropathy. Clin Nephrol 25:186-192, 1986
397. Ahmed J, Ward TP, Bursell SE, Aiello LM, Cavallerano JD, Vigersky RA: The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care 29:2205-2209, 2006
398. Dailey GE, Boden GH, Creech RH, et al: Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism 49:1491-1495, 2000
399. Reichard P, Pihl M, Rosenqvist U, Sule J: Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 39:1483-1488, 1996
400. Barnett AH, Bain SC, Bouter P, et al: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952-1961, 2004
401. Bakris GL, Williams M, Dworkin L, et al: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
402. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
403. Perry HM Jr, Miller JP, Fornoff JR, et al: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587-594, 1995
404. Bakris GL, Slataper R, Vicknair N, Sadler R: ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 8:2-6, 1994
405. Parving HH, Hovind P: Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 4:387-393, 2002
406. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
407. Bakris GL, Smith AC, Richardson DJ, et al: Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: A randomised, multi-centre pilot study. J Hum Hypertens 16:185-191, 2002
408. Bakris GL, Weir M: ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: What's the evidence. J Clin Hypertens (Greenwich) 4:420-423, 2002
409. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23:B54-B64, 2000 (suppl 2)
410. Bakris GL: The role of combination antihypertensive therapy and the progression of renal disease hypertension: Looking toward the next millennium. Am J Hypertens 11:158S-162S, 1998 (suppl)
411. Melian EB, Jarvis B: Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 62:787-816, 2002
412. Weir MR, Smith DH, Neutel JM, Bedigian MP: Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake. Am J Hypertens 14:665-671, 2001
413. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65:1991-2002, 2004
414. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963-1974, 1995
415. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 17:72-80, 1997
416. Sica DA, Bakris GL: Type 2 diabetes: RENAAL and IDNT—The emergence of new treatment options. J Clin Hypertens (Greenwich) 4:52-57, 2002
417. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106:672-678, 2002
418. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 29:744-750, 1997
419. Ruggenenti P, Fassi A, Ilieva AP, et al: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951, 2004
420. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14:992-999, 2003
421. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63:1874-1880, 2003
422. Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan And Lisinopril Microalbuminuria (CALM) Study. BMJ 321:1440-1444, 2000
423. Hart PD, Bakris GL: Managing hypertension in the diabetic patient, in Egan BM, Basile JN, Lackland DT (eds): Hot Topics in Hypertension. Philadelphia, PA, Hanley & Belfus, 2004, pp 249-252
424. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097, 2002
425. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
426. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M: Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy. Am J Nephrol 24:543-548, 2004
427. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124, 2003
428. Casas JP, Chua W, Loukogeorgakis S, et al: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366:2026-2033, 2005
429. Tarnow L, Sato A, Ali S, Rossing P, Nielsen FS, Parving HH: Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care 22:491-494, 1999
430. Sawicki PT: Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. Diabetes Treatment and Teaching Programmes Working Group. Nephrol Dial Transplant 12:1890-1899, 1997
431. Velussi M, Brocco E, Frigato F, et al: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
432. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
433. National Diabetes Data Group: Diabetes in America (ed 2). Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995
434. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
435. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
436. Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138:593-602, 2003
437. Barrett-Connor E, Grundy SM, Holdbrook MJ: Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 115:657-663, 1982
438. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM: LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496-1502, 1992
439. Jenkins AJ, Lyons TJ, Zheng D, et al: Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney Int 64:817-828, 2003
440. Quaschning T, Schomig M, Keller M, et al: Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 10:332-341, 1999
441. Armitage J, Bowman L: Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 15:439-446, 2004
442. Cheung BM, Lauder IJ, Lau CP, Kumana CR: Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57:640-651, 2004
443. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995
444. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996
445. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
446. Wanner C, Krane V, Marz W, et al: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): Demographic and baseline characteristics. Kidney Blood Press Res 27:259-266, 2004
447. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887-1893, 2002
448. Seliger SL, Weiss NS, Gillen DL, et al: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304, 2002
449. Mason NA, Bailie GR, Satayathum S, et al: HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-126, 2005
450. Hommel E, Andersen P, Gall MA, et al: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35:447-451, 1992
451. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H: Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449-454, 2001
452. Lam KS, Cheng IK, Janus ED, Pang RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38:604-609, 1995
453. Nagai T, Tomizawa T, Nakajima K, Mori M: Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 7:91-96, 2000
454. Tonolo G, Melis MG, Formato M, et al: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30:980-987, 2000
455. Appel GB, Radhakrishnan J, Avram MM, et al: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 26:1402-1407, 2003
456. Nielsen S, Schmitz O, Moller N, et al: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36:1079-1086, 1993
457. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 27:997-1002, 1997
458. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40:567-572, 2002
459. Phillips PS, Haas RH, Bannykh S, et al: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585, 2002
460. LaRosa JC, Grundy SM, Waters DD, et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435, 2005
461. Zhang A, Vertommen J, Van Gaal L, De Leeuw I: Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 29:189-194, 1995
462. Pijls LT, de Vries H, Donker AJ, van Eijk JT: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: A randomized trial. Nephrol Dial Transplant 14:1445-1453, 1999
463. Vora JP, Thomas D, Peters JR, Coles GA, Williams JD: Preservation of renal haemodynamic response to an oral protein load in non-insulin-dependent diabetes mellitus. Diabet Med 10:715-719, 1993
464. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 25:202-212, 2002
465. Cutler JA, Obarzanek E: Nutrition and blood pressure: Is protein one link? Toward a strategy of hypertension prevention. Ann Intern Med 143:74-75, 2005
466. Gross JL, Zelmanovitz T, Moulin CC, et al: Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: A randomized crossover trial. Diabetes Care 25:645-651, 2002
467. Food and Nutrition Board, Institute of Medicine of the National Academies: Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids (macronutrients). Washington, DC, National Academies Press, 2005
468. Bouhanick B, Suraniti S, Berrut G, et al: Relationship between fat intake and glomerular filtration rate in normotensive insulin-dependent diabetic patients. Diabete Metab 21:168-172, 1995
469. Dullaart RP, Beusekamp BJ, Meijer S, Hoogenberg K, van Doormaal JJ, Sluiter WJ: Long-term effects of linoleic-acid-enriched diet on albuminuria and lipid levels in type 1 (insulin-dependent) diabetic patients with elevated urinary albumin excretion. Diabetologia 35:165-172, 1992
470. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S: Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids 25:541-545, 1990
471. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S: Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care 24:805-810, 2001
472. Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving HH: Fish oil in diabetic nephropathy. Diabetes Care 19:1214-1219, 1996
473. Goeddeke-Merickel CM: The goals of comprehensive and integrated disease state management for diabetic kidney-disease patients. Adv Chronic Kidney Dis 12:236-242, 2005
474. McMurray SD, Johnson G, Davis S, McDougall K: Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 40:566-575, 2002
475. Milas NC, Nowalk MP, Akpele L, et al: Factors associated with adherence to the dietary protein intervention in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 95:1295-1300, 1995
476. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757, 2002
477. Wiggins KL (ed): Nutrition care of adult pre-ESRD patients, in Guidelines for Nutrition Care of Renal Patients (ed 3). Chicago, IL, American Dietetic Asssociation, 2002, pp 6-13
478. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324:78-84, 1991
479. Brouhard BH, LaGrone L: Effect of dietary protein restriction on functional renal reserve in diabetic nephropathy. Am J Med 89:427-431, 1990
480. Muhlhauser I, Prange K, Sawicki PT, et al: Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia 39:212-219, 1996
481. Facchini FS, Saylor KL: A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52:1204-1209, 2003
482. Wheeler ML, Fineberg SE, Fineberg NS, Gibson RG, Hackward LL: Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: Effects on renal, glycemic, and lipid parameters. Diabetes Care 25:1277-1282, 2002
483. Bakris GL, Smith A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125:201-204, 1996
484. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004
485. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J, for the DIABHYCAR-Study-Investigators: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: Randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495, 2004
486. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-720, 1998
487. Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576-1581, 1997
488. Capes SE, Gerstein HC, Negassa A, Yusuf S: Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 23:377-380, 2000
489. Gaede P, Hansen HP, Parving HH, Pedersen O: Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant 18:539-542, 2003
490. Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 18:756-760, 2001
491. Lonn E, Yusuf S, Hoogwerf B, et al: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25:1919-1927, 2002
492. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
493. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD: HRT does not improve urinary albumin excretion in postmenopausal diabetic women. Diabetes Res Clin Pract 60:33-39, 2003
494. Hoshino T, Ikeda T: Inhibitory effect of ibudilast on urinary albumin excretion in type 2 diabetes mellitus with microalbuminuria. Nephron 90:154-157, 2002
495. Shindo H, Tawata M, Yokomori N, Hosaka Y, Ohtaka M, Onaya T: Iloprost decreases urinary albumin excretion rate in patients with diabetic nephropathy. Diabetes Res Clin Pract 21:115-122, 1993
496. Young BA, Pugh JA, Maynard C, Reiber G: Diabetes and renal disease in veterans. Diabetes Care 27:B45-B49, 2004 (suppl 2)
497. Mau MK, West M, Sugihara J, Kamaka M, Mikami J, Cheng SF: Renal disease disparities in Asian and Pacific-based populations in Hawai'i. J Natl Med Assoc 95:955-963, 2003
498. Thompson CF, Simmons D, Collins JF, Cecil A: Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus. Diabet Med 18:40-46, 2001
499. Pugh JA, Stern MP, Haffner SM, Eifler CW, Zapata M: Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol 127:135-144, 1988
500. Bowden DW, Colicigno CJ, Langefeld CD, et al: A genome scan for diabetic nephropathy in African Americans. Kidney Int 66:1517-1526, 2004
501. Gitter J, Langefeld CD, Rich SS, Pedley CF, Bowden DW, Freedman BI: Prevalence of nephropathy in black patients with type 2 diabetes mellitus. Am J Nephrol 22:35-41, 2002
502. Imperatore G, Knowler WC, Nelson RG, Hanson RL: Genetics of diabetic nephropathy in the Pima Indians. Curr Diab Rep 1:275-281, 2001
503. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV: Ethnic disparities in diabetic complications in an insured population. JAMA 287:2519-2527, 2002
504. Krop JS, Coresh J, Chambless LE, et al: A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: The Atherosclerosis Risk in Communities Study. Arch Intern Med 159:1777-1783, 1999
505. Rate RG, Knowler WC, Morse HG, et al: Diabetes mellitus in Hopi and Navajo Indians. Prevalence of microvascular complications. Diabetes 32:894-899, 1983
506. Lemley KV: A basis for accelerated progression of diabetic nephropathy in Pima Indians. Kidney Int Suppl 83:S38-S42, 2003
507. Sievers ML, Bennett PH, Roumain J, Nelson RG: Effect of hypertension on mortality in Pima Indians. Circulation 100:33-40, 1999
508. Tentori F, Stidley CA, Scavini M, et al: Prevalence of hematuria among Zuni Indians with and without diabetes: The Zuni Kidney Project. Am J Kidney Dis 41:1195-1204, 2003
509. Hoy WE, Mathews JD, McCredie DA, et al: The multidimensional nature of renal disease: Rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int 54:1296-1304, 1998
510. Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR: Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 15:1801-1807, 2000
511. Sinha R, Fisch G, Teague B, et al: Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802-810, 2002
512. Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288:1728-1732, 2002
513. American Diabetes Association: Type 2 diabetes in children and adolescents. Diabetes Care 23:381-389, 2000
514. Botero D, Wolfsdorf JI: Diabetes mellitus in children and adolescents. Arch Med Res 36:281-290, 2005
515. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM: Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III. Kidney Int 61:2165-2175, 2002
516. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K: Renal impairment associated with diabetes in the elderly. Diabetes Care 27:2648-2653, 2004
517. Otiniano ME, Markides KS, Ottenbacher K, Ray LA, Du XL: Self-reported diabetic complications and 7-year mortality in Mexican American elders. Findings from a community-based study of five Southwestern states. J Diabetes Complications 17:243-248, 2003
518. Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS: Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: Data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 26:3054-3060, 2003
519. Mix TC, St Peter WL, Ebben J, et al: Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 42:972-981, 2003
520. Ekbom P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Molvig J, Mathiesen ER: Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 24:1739-1744, 2001
521. Hiilesmaa V, Suhonen L, Teramo K: Glycaemic control is associated with pre-eclampsia but not with pregnancy-induced hypertension in women with type I diabetes mellitus. Diabetologia 43:1534-1539, 2000
522. Biesenbach G, Grafinger P, Zazgornik J, Helmut, Stoger: Perinatal complications and three-year follow up of infants of diabetic mothers with diabetic nephropathy stage IV. Ren Fail 22:573-580, 2000
523. Gordon M, Landon MB, Samuels P, Hissrich S, Gabbe SG: Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol 87:401-409, 1996
524. Kimmerle R, Zass RP, Cupisti S, et al: Pregnancies in women with diabetic nephropathy: Long-term outcome for mother and child. Diabetologia 38:227-235, 1995
525. Dunne FP, Chowdhury TA, Hartland A, et al: Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy. QJM 92:451-454, 1999
526. Sibai BM, Caritis S, Hauth J, et al: Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 182:364-369, 2000
527. Vaarasmaki MS, Hartikainen A, Anttila M, Pramila S, Koivisto M: Factors predicting peri- and neonatal outcome in diabetic pregnancy. Early Hum Dev 59:61-70, 2000
528. Nielsen GL, Sorensen HT, Nielsen PH, Sabroe S, Olsen J: Glycosylated hemoglobin as predictor of adverse fetal outcome in type 1 diabetic pregnancies. Acta Diabetol 34:217-222, 1997
529. The Diabetes Control and Complications Trial Research Group: Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 23:1084-1091, 2000
530. Hemachandra A, Ellis D, Lloyd CE, Orchard TJ: The influence of pregnancy on IDDM complications. Diabetes Care 18:950-954, 1995
531. Mackie AD, Doddridge MC, Gamsu HR, Brudenell JM, Nicolaides KH, Drury PL: Outcome of pregnancy in patients with insulin-dependent diabetes mellitus and nephropathy with moderate renal impairment. Diabet Med 13:90-96, 1996
532. Purdy LP, Hantsch CE, Molitch ME, et al: Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care 19:1067-1074, 1996
533. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183:S1-S22, 2000 (suppl)
534. Podymow T, August P, Umans JG: Antihypertensive therapy in pregnancy. Semin Nephrol 24:616-625, 2004
535. August P, Lindheimer M: Chronic hypertension and pregnancy, in Lindheimer MD, Roberts JM, Cunningham FG (eds): Chelsey's Hypertensive Disorders in Pregnancy (ed 2). Stamford, CT, Appleton & Lange, 1999, pp 650-653
536. Bar J, Chen R, Schoenfeld A, et al: Pregnancy outcome in patients with insulin dependent diabetes mellitus and diabetic nephropathy treated with ACE inhibitors before pregnancy. J Pediatr Endocrinol Metab 12:659-665, 1999
537. Hod M, van Dijk DJ, Karp M, et al: Diabetic nephropathy and pregnancy: The effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant 10:2328-2333, 1995
538. Shotan A, Widerhorn J, Hurst A, Elkayam U: Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96:451-456, 1994
539. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al: Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443-2451, 2006
540. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR: Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 193:118-124, 2005
541. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O: A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 343:1134-1138, 2000
542. Preconception care of women with diabetes. Diabetes Care 26:S91-S93, 2003 (suppl 1)
543. Gestational diabetes mellitus. Diabetes Care 26:S103-S105, 2003 (suppl 1)
544. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 105:675-685, 2005
545. Miller VT: Dyslipoproteinemia in women. Special considerations. Endocrinol Metab Clin North Am 19:381-398, 1990
546. Napoli C, D'Armiento FP, Mancini FP, et al: Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 100:2680-2690, 1997
547. Levitt NS, Bradshaw D, Zwarenstein MF, Bawa AA, Maphumolo S: Audit of public sector primary diabetes care in Cape Town, South Africa: High prevalence of complications, uncontrolled hyperglycaemia, and hypertension. Diabet Med 14:1073-1077, 1997
548. Wesson DE: Can risk factor modification prevent nephropathy in type 2 diabetes mellitus? Am J Kidney Dis 36:1054-1056, 2000
549. KEEP: Kidney Early Evaluation Program. Annual atlas of the National Kidney Foundation's early evaluation program data. Am J Kidney Dis 42:S1-S61, 2003 (suppl 4)
550. Acton KJ, Shields R, Rith-Najarian S, et al: Applying the diabetes quality improvement project indicators in the Indian Health Service primary care setting. Diabetes Care 24:22-26, 2001
551. Burrows NR, Narva AS, Geiss LS, Engelgau MM, Acton KJ: End-stage renal disease due to diabetes among southwestern American Indians, 1990-2001. Diabetes Care 28:1041-1044, 2005
552. Geiss L, Engelgau M, Pogach L, et al: A national progress report on diabetes: Successes and challenges. Diabetes Technol Ther 7:198-203, 2005
553. Hoy WE, Wang Z, Baker PR, Kelly AM: Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl 83:S66-S73, 2003
554. Mani MK: Prevention of chronic renal failure at the community level. Kidney Int Suppl 83:S86-S89, 2003
555. Ifudu O, Dawood M, Homel P, Friedman EA: Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 28:841-845, 1996
556. Dean HJ: Dancing with many different ghosts: Treatment of youth with type 2 diabetes. Diabetes Care 25:237-238, 2002
557. Miodovnik M, Rosenn BM, Khoury JC, Grigsby JL, Siddiqi TA: Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol 174:1180-1189, 1996
558. Rossing K, Jacobsen P, Hommel E, et al: Pregnancy and progression of diabetic nephropathy. Diabetologia 45:36-41, 2002
559. Vaarasmaki M, Anttila M, Pirttiaho H, Hartikainen AL: Are recurrent pregnancies a risk in type 1 diabetes? Acta Obstet Gynecol Scand 81:1110-1115, 2002
560. Reece EA, Winn HN, Hayslett JP, Coulehan J, Wan M, Hobbins JC: Does pregnancy alter the rate of progression of diabetic nephropathy? Am J Perinatol 7:193-197, 1990
561. Geiss LS, Rolka DB, Engelgau MM: Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 22:42-48, 2002
562. United Kingdom Prospective Diabetes Study (UKPDS): 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
563. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
564. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR: Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
565. DiMatteo MR: Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 42:200-209, 2004
566. Glasgow RE, Hampson SE, Strycker LA, Ruggiero L: Personal-model beliefs and social-environmental barriers related to diabetes self-management. Diabetes Care 20:556-561, 1997
567. Litwak LE, Mileo Vaglio R, Alvarez A, Gutman RA: [Self monitoring of capillary blood glucose. Evaluation of long-term results (3 to 7 years)]. Medicina (B Aires) 59:71-78, 1999
568. Beckles GL, Engelgau MM, Narayan KM, Herman WH, Aubert RE, Williamson DF: Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care 21:1432-1438, 1998
569. Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD: Frequency of blood glucose monitoring in relation to glycaemic control: Observational study with diabetes database. BMJ 319:83-86, 1999
570. Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 27:1218-1224, 2004
571. Kamiya A, Ohsawa I, Fujii T, et al: A clinical survey on the compliance of exercise therapy for diabetic outpatients. Diabetes Res Clin Pract 27:141-145, 1995
572. Kravitz RL, Hays RD, Sherbourne CD, et al: Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med 153:1869-1878, 1993
573. Cerkoney KA, Hart LK: The relationship between the health belief model and compliance of persons with diabetes mellitus. Diabetes Care 3:594-598, 1980
574. Flauto RP, Leon JB, Sehgal AR: The provision and outcomes of diabetic care of hemodialysis patients. Am J Kidney Dis 41:125-131, 2003
575. Mensing C, Boucher J, Cypress M, et al: National standards for diabetes self-management education. Diabetes Care 27:S143-S150, 2004 (suppl 1)
576. Norris SL, Engelgau MM, Narayan KM: Effectiveness of self-management training in type 2 diabetes: A systematic review of randomized controlled trials. Diabetes Care 24:561-587, 2001
577. Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA: Diabetes patient education: A meta-analysis and meta-regression. Patient Educ Couns 52:97-105, 2004
578. Wing RR, Goldstein MG, Acton KJ, et al: Behavioral science research in diabetes: Lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 24:117-123, 2001
579. Hypertension Prevention Trial Research Group: The Hypertension Prevention Trial: Three-year effects of dietary changes on blood pressure. Arch Intern Med 150:153-162, 1990
580. Ciechanowski PS, Katon WJ, Russo JE: Depression and diabetes: Impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 160:3278-3285, 2000
581. Hurley AC, Shea CA: Self-efficacy: strategy for enhancing diabetes self-care. Diabetes Educ 18:146-150, 1992
582. Johnston-Brooks CH, Lewis MA, Garg S: Self-efficacy impacts self-care and HbA1c in young adults with type I diabetes. Psychosom Med 64:43-51, 2002
583. McCaul KD, Glasgow RE, Schafer LC: Diabetes regimen behaviors. Predicting adherence. Med Care 25:868-881, 1987
584. Senecal C, Nouwen A, White D: Motivation and dietary self-care in adults with diabetes: Are self-efficacy and autonomous self-regulation complementary or competing constructs? Health Psychol 19:452-457, 2000
585. Schillinger D, Grumbach K, Piette J, et al: Association of health literacy with diabetes outcomes. JAMA 288:475-482, 2002
586. Swift CS, Armstrong JE, Beerman KA, Campbell RK, Pond-Smith D: Attitudes and beliefs about exercise among persons with non-insulin-dependent diabetes. Diabetes Educ 21:533-540, 1995
587. Smedley BD, Stith AY, Nelson AR: Unequal Treatment Confronting Racial and Ethnic Disparities in Healthcare. Washington, DC, Institute of Medicine, National Academy Press, 2002
588. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM: Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321:1074-1079, 1989
589. Sarkisian CA, Brown AF, Norris KC, Wintz RL, Mangione CM: A systematic review of diabetes self-care interventions for older, African American, or Latino adults. Diabetes Educ 29:467-479, 2003
590. Bruce DG, Casey GP, Grange V, et al: Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: The Fremantle Cognition in Diabetes Study. Diabetes Res Clin Pract 61:59-67, 2003
591. Logroscino G, Kang JH, Grodstein F: Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 328:548, 2004
592. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB: Lower cognitive function in the presence of obesity and hypertension: The Framingham heart study. Int J Obes Relat Metab Disord 27:260-268, 2003
593. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM: Self-management education for adults with type 2 diabetes: A meta-analysis of the effect on glycemic control. Diabetes Care 25:1159-1171, 2002
594. Steed L, Cooke D, Newman S: A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns 51:5-15, 2003
595. Norris SL, Nichols PJ, Caspersen CJ, et al: Increasing diabetes self-management education in community settings. A systematic review. Am J Prev Med 22:S39-S66, 2002 (suppl 4)
596. Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL: Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educator 29:488-501, 2003
597. Balas EA, Krishna S, Kretschmer RA, Cheek TR, Lobach DF, Boren SA: Computerized knowledge management in diabetes care. Med Care 42:610-621, 2004
598. Atkins D, Best D, Briss PA, et al: Grading quality of evidence and strength of recommendations. BMJ 328:1490, 2004